BMO Capital analyst Sean Dodge upgraded Icon (ICLR) to Outperform from Market Perform with a price target of $130, up from $100. The firm’s recent analysis indicates continued improvements in Icon’s large pharma backdrop. In additions, the shares are trading at a multi-decade low valuation, the analyst tells investors in a research note. BMO believes current share levels overly discount the risks from Icon’s accounting review and longer-term AI fears overhanging the space. It sees current levels as an attractive entry point.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ICLR:
- Icon, Advarra enter partnership, introduces ‘research-ready’ site network model
- ICON plc options imply 2.8% move in share price post-earnings
- Icon price target lowered to $120 from $200 at Citi
- ICON plc options imply 4.1% move in share price post-earnings
- Icon price target lowered to $120 from $200 at Barclays
